Tumor progression, and particularly that of some neuroectodermal tumors (e.g., neuroblastoma and melanoma) causes most cancer-related morbidity and mortality. Thus, understanding and preventing progression is critical to developing effective cancer therapies. The synthesis and shedding of the membrane glycosphingolipids, gangliosides, has been strongly implicated by our past findings and the work of others in contributing to processes that facilitate tumor progression. Moreover, we have made significant progress in elucidating basic mechanisms in vitro by which gangliosides modulate the behavior of host cells found in the tumor microenvironment. We obtained clear evidence for the impact of ganglioside synthesis and shedding on cell signaling and on angiogenic responses of human endothelial cells, and found that pharmacological inhibition of glycosphingolipid synthesis has a striking inhibitory effect upon tumor growth. Based on these findings we hypothesize that gangliosides enhance tumor progression in vivo, and that interference with the synthesis of tumor gangliosides will impede tumor progression in vivo. However, an adequate animal model system of specific and constitutive inhibition of ganglioside synthesis in vivo has been lacking, and here we propose to fill this gap, by studying tumor progression in two different and complementary novel animal model systems that we are creating.
In aim 1 we will develop two oncogene transformed ganglioside-deficient fibroblast tumor cell lines, one by GM3synthase/GM2synthase double knockout and the other by 4-OH-tamoxifen-inducible, cre-mediated deletion of glucosylceramide synthase (GCS).
In aim 2 we will develop a unique ganglioside-depleted rodent tumor model by cre-mediated excision of the GCS gene in an orthotopic neuroectodermal (transgenic melanoma) tumor system in vivo.
In Aim 3 we will comprehensively determine how ganglioside knockout in these ganglioside-depleted tumor systems affects tumor progression, providing the first unambiguous insights in vivo in a genetically controlled and stable system. Accomplishment of these aims will begin to elucidate the role and basic mechanisms by which gangliosides modulate tumor progression in vivo. This knowledge will lead to our ultimate goals of full delineation of the biological activity of tumor gangliosides in tumor progression and the development of novel therapeutic approaches to human cancer built upon this knowledge.

Public Health Relevance

Understanding and prevention of tumor progression is critical for development of effective cancer therapies. The goal of the research proposed in this application is to determine exactly how production and shedding by tumor cells of a special type of lipids, named gangliosides, helps tumors to grow. The results of our studies will potentially allow modulation of ganglioside production/activity by tumors, which will in turn enable design of novel and effective treatments of cancer patients.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Tumor Progression and Metastasis Study Section (TPM)
Program Officer
Ault, Grace S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Children's Research Institute
United States
Zip Code
Wondimu, Assefa; Liu, Yihui; Su, Yan et al. (2014) Gangliosides drive the tumor infiltration and function of myeloid-derived suppressor cells. Cancer Res 74:5449-57
Liu, Yihui; Wondimu, Assefa; Yan, Su et al. (2014) Tumor gangliosides accelerate murine tumor angiogenesis. Angiogenesis 17:563-71
Jales, Alessandra; Falahati, Rustom; Mari, Elisabeth et al. (2011) Ganglioside-exposed dendritic cells inhibit T-cell effector function by promoting regulatory cell activity. Immunology 132:134-43
Dong, Lixian; Liu, Yihui; Colberg-Poley, Anamaris M et al. (2011) Induction of GM1a/GD1b synthase triggers complex ganglioside expression and alters neuroblastoma cell behavior; a new tumor cell model of ganglioside function. Glycoconj J 28:137-47
Liu, Y; Yan, S; Wondimu, A et al. (2010) Ganglioside synthase knockout in oncogene-transformed fibroblasts depletes gangliosides and impairs tumor growth. Oncogene 29:3297-306
Shevchuk, Nikolai A; Hathout, Yetrib; Epifano, Olga et al. (2007) Alteration of ganglioside synthesis by GM3 synthase knockout in murine embryonic fibroblasts. Biochim Biophys Acta 1771:1226-34
Kaucic, Karen; Liu, Yihui; Ladisch, Stephan (2006) Modulation of growth factor signaling by gangliosides: positive or negative? Methods Enzymol 417:168-85
Liu, Yihui; Li, Ruixiang; Ladisch, Stephan (2004) Exogenous ganglioside GD1a enhances epidermal growth factor receptor binding and dimerization. J Biol Chem 279:36481-9
Shevchuk, Nikolai A; Bryksin, Anton V; Nusinovich, Yevgeniya A et al. (2004) Construction of long DNA molecules using long PCR-based fusion of several fragments simultaneously. Nucleic Acids Res 32:e19
Guerrera, Michael; Ladisch, Stephan (2003) N-butyldeoxynojirimycin inhibits murine melanoma cell ganglioside metabolism and delays tumor onset. Cancer Lett 201:31-40

Showing the most recent 10 out of 32 publications